Efficacy and safety of aclidinium/ formoterol versus salmeterol/fluticasone: A phase 3 COPD study

European Respiratory Journal

Volumn 48, Issue 4, 2016, Pages 1030-1039

  Vogelmeier, Claus ^a   Paggiaro, Pier Luigi ^b   Dorca, Jordi ^c   Sliwinski, Pawel ^d   Mallet, Marcel ^e   Kirsten, Anne Marie ^f   Beier, Jutta ^g   Seoane, Beatriz ^h   Segarra, Rosa Maria ^h   Leselbaum, Anne ⁱ  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^d NATIONAL TUBERCULOSIS AND LUNG DISEASES RESEARCH INSTITUTE   (Poland)

^e Moncton Medical Clinic   (Canada)

^f Member of the German Center for Lung Research   (Germany)

^g Institut fur Atemwegsforschung INSAF   (Germany)

^h ASTRAZENECA   (United Kingdom)

ⁱ Almirall SA ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; ACLIDINIUM BROMIDE; BRONCHODILATING AGENT; FLUTICASONE; FORMOTEROL FUMARATE; SALMETEROL XINAFOATE; TROPANE DERIVATIVE;

ADULT; ARTICLE; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPHONIA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HEALTH STATUS; HEART DISEASE; HEART FAILURE; HEART RIGHT VENTRICLE DYSPLASIA; HUMAN; HYPERTENSION; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; OROPHARYNX PAIN; PATIENT PREFERENCE; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SUDDEN CARDIAC DEATH; TASTE DISORDER; THRUSH; AGED; CLINICAL TRIAL; MIDDLE AGED; PULMONOLOGY; QUESTIONNAIRE; SMOKING; SPIROMETRY; TREATMENT OUTCOME;

ADULT; AGED; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; FEMALE; FLUTICASONE; FLUTICASONE-SALMETEROL DRUG COMBINATION; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY MEDICINE; SALMETEROL XINAFOATE; SMOKING; SPIROMETRY; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; TROPANES;

EID: 84990047472     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00216-2016     Document Type: Article

References (23)

1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. 2015. Available from: www.goldcopd.org
2. Cazzola M, Matera MG. The effective treatment of COPD: Anticholinergics and what else? Drug Discov Today Ther Strateg 2006; 3: 277-286.
3. Cazzola M, Calzetta L, Matera MG. β2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011; 163: 4-17.
4. Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012; 64: 450-504.
5. Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev 2014; 3: CD010844.
6. Latorre M, Novelli F, Vagaggini B, et al. Differences in the efficacy and safety among inhaled corticosteroids (ICS)/ long-acting β2-agonists (LABA) combinations in the treatment of chronic obstructive pulmonary disease (COPD): role of ICS. Pulm Pharmacol Ther 2015; 30: 44-50.
7. Wilkie M, Finch S, Schembri S. Inhaled corticosteroids for chronic obstructive pulmonary disease - the shifting treatment paradigm. COPD 2015; 12: 582-590.
8. European Medicines Agency. Duaklir Genuair. www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/ medicines/003745/human-med-001811.jsp&mid=WC0b01ac058001d124 Date last updated: June 21, 2016. Date last accessed: July 15, 2016.
9. Singh D, Jones PW, Bateman ED, et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014; 14: 178-189.
10. D'Urzo AD, Rennard SI, Kerwin EM, et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/ formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014; 15: 123-141.
11. Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res 2015; 16: 92.
12. Leidy NK, Wilcox TK, Jones PW, et al. Development of the EXAcerbations of Chronic obstructive pulmonary disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health 2010; 13: 965-975.
13. Leidy NK, Wilcox TK, Jones PW, et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations: reliability and validity of a patient-reported diary. Am J Respir Crit Care Med 2011; 183: 323-329.
14. Hareendran A, Palsgrove AC, Mocarski M, et al. The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease. Health Qual Life Outcomes 2013; 11: 104.
15. Mocarski M, Zaiser E, Trundell D, et al. Evaluation of the psychometric properties of the Nighttime Symptoms of COPD Instrument. Int J Chron Obstruct Pulmon Dis 2015; 10: 475-487.
16. Mocarski M, Hareendran A, Jen MH, et al. Evaluation of the psychometric properties of the early morning symptoms of COPD instrument (EMSCI). Value Health 2014; 17: A179.
17. International Conference on Harmonisation E9 Expert Working Group. ICH harmonised tripartite guideline statistical principles for clinical trials E9. Stat Med 1999; 18: 1905-1942.
18. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med 2013; 1: 51-60.
19. Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis 2015; 10: 1015-1026.
20. Donohue JF, Worsley S, Zhu CQ, et al. Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations. Respir Med 2015; 109: 870-881.
21. Gupta N, Pinto LM, Morogan A, et al. The COPD assessment test: a systematic review. Eur Respir J 2014; 44: 873-884.
22. Jones PW, Adamek L, Nadeau G, et al. Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification. Eur Respir J 2013; 42: 647-654.
23. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294.